These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37112972)

  • 1. HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing.
    Tao K; Rhee SY; Tzou PL; Osman ZA; Pond SLK; Holmes SP; Shafer RW
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid HIV-1 genotyping assay for the detection of capsid mutations.
    Margot N; Naik V; Nekkalapudi A; Boopathy A; Falkard B; Callebaut C
    J Med Virol; 2023 Dec; 95(12):e29292. PubMed ID: 38063404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir.
    Troyano-Hernáez P; Reinosa R; Holguín Á
    Front Microbiol; 2022; 13():854974. PubMed ID: 35495642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
    Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
    mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
    Prather C; Lee A; Yen C
    Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations.
    Schommers P; Martrus G; Matschl U; Sirignano M; Lütgehetmann M; Richert L; Hope TJ; Fätkenheuer G; Altfeld M
    J Virol; 2016 Aug; 90(16):7579-7586. PubMed ID: 27279617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
    Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
    J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic diversity of capsid protein (p24) in human immunodeficiency virus type-1 (HIV-1) variants circulating in the Russian Federation].
    Kuznetsova AI; Munchak IM; Lebedev AV; Tumanov AS; Kim KV; Antonova AA; Ozhmegova EN; Pronin AY; Drobyshevskaya EV; Kazennova EV; Bobkova MR
    Vopr Virusol; 2023 Mar; 68(1):66-78. PubMed ID: 36961237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.
    Brockman MA; Schneidewind A; Lahaie M; Schmidt A; Miura T; Desouza I; Ryvkin F; Derdeyn CA; Allen S; Hunter E; Mulenga J; Goepfert PA; Walker BD; Allen TM
    J Virol; 2007 Nov; 81(22):12608-18. PubMed ID: 17728232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
    Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
    Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
    Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.